Core Viewpoint - Kangchen Pharmaceutical reported a significant increase in revenue and profit for the six months ending June 30, 2025, indicating strong business performance and growth potential in the pharmaceutical sector [1] Financial Performance - The company's revenue reached RMB 1.569 billion, representing a year-on-year growth of approximately 23.7% [1] - The profit attributable to equity shareholders was RMB 498 million, showing a year-on-year increase of about 24.6% [1] - Basic and diluted earnings per share were RMB 0.59 and RMB 0.58, respectively [1] - The company proposed an interim dividend of HKD 0.33 per share [1] Gross Margin and Profitability - The group's gross profit increased by approximately 27.6%, with the gross margin rising to 77.1% [1] - The improvement in gross margin was primarily due to sales growth and a decrease in the procurement prices of traditional Chinese medicine raw materials [1] Product Performance - Sales of nephrology product series grew by 28.0%, with Uremic Clear maintaining its leading position [1] - Sales of maternal and pediatric product series increased by 17.5%, becoming the second-largest source of revenue [1] - Sales of medical imaging contrast agents rose by 22.0% [1] - Other product series also recorded varying degrees of growth [1]
康臣药业上半年权益股东应占溢利增长24.6%